Pharmaceutical Executive January 14, 2026
Graham Goodrich, CCO, Apnimed, outlines how advances in diagnostics, growing recognition of sleep apnea’s systemic impact, and emerging oral therapies are driving renewed momentum in sleep medicine as Apnimed advances toward commercialization.
Pharmaceutical Executive; As you arrive this year at The J.P. Morgan Healthcare Conference what signals are you seeing around renewed interest in sleep medicine, and how is that influencing your positioning in the space?
Graham Goodrich: I think what we’ve been seeing for quite some time is that we believe that the category which we’re interested in, in our lead product candidate AD109 is focused on obstructive sleep apnea, and we’re seeing a bit of a revolution in this category. It has been dominated by devices...
Today's Sponsors
Today's Sponsor